Simultaneous Sessions

CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDEDEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS
C Terragna, D Remondini, G Martinelli, P Tosi, E Zamagni, P Tacchetti, G Perrone, A Brioli, M Ceccolini, N Testoni, G Marzocchi, G Castellani, S Durante, F Di Raimondo, F Patriarca, L Catalano, L Masini, A Ledda, E Angelucci, P Galieni, A Gozzetti, M Baccarani, M Cavo („Seràgnoli„ Institute of Hematology, Bologna, Italy)

DEVELOPMENT OF PERIPHERAL NEUROPATHY IN MULTIPLE MYELOMA PATIENTS INCIDENCE, MOLECULAR CHARACTERIZATION AND EFFECT ON RESPONSE IN BORTEZOMIB VS CONVENTIONAL TREATMENT
A Broyl, S Corthals, Y De Knegt, B van der Holt, H Goldschmidt, H Lokhorst, B Durie, B Van Ness, P Sonneveld (Erasmusmc, Rotterdam, The Netherlands)

GENETIC VARIATIONS ASSOCIATED WITH TREATMENT RESPONSE, PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA IN THE HOVON 50/GMMG-HD3 TRIALS
S Corthals, H Lokhorst, Y de Knegt, B van der Holt, H Goldschmidt, D Hose, U Bertsch, S Zweegman, E Vellenga, B Durie, B van Ness, P Sonneveld (Erasmus University Medical Center, Rotterdam, The Netherlands)

THE CLINICAL AND BIOLOGICAL SIGNIFICANCE OF THE IMMUNOPHENOTYPIC ASSESSMENT OF CD81 IN MULTIPLE MYELOMA CLONAL PLASMA CELLS
B Paiva, M Vidriales, N Gutierrez, M Montalban, A Oriol, J Martinez, M Mateos, L Lopez-Corral, J Perez, M Sarasquete, J Laraña, F De Arriba, L Palomera, M Echebeste, M Terol, R De Paz, A Martin, J Hernandez, Y Gonzalez, R Martinez, J Blade, J Lahuerta, J San Miguel (Hospital Universitario Salamanca, Salamanca, Spain)

MICRORNAS CHANGES OCCUR IN MULTIPLE MYELOMA CELLS IN THE CONTEXT OF BONE MARROW MILIEU
A Roccaro, A Sacco, A Azab, F Azab, T Ngo, P Quang, P Maiso, G Rossi, M Ghobrial (Spedali Civili di Brescia, Brescia, Italy)

PREVALENCE AND DETERMINANTS OF BLEEDING IN SEVERE VON WILLEBRAND DISEASE TYPE 3: RESULTS OF RETRO/PROSPECTIVE STUDIES IN A COHORT OF 105/52 ITALIAN PATIENTS
A Federici, A Iorio, G Castaman, MG Mazzucconi, M Morfini, A Rocino, M Schiavoni, P Mannucci (University of Milan, Milan, Italy)

PLATELET DYSFUNCTION AND MDS FEATURES DUE TO NOVEL SOMATIC GATA1 MUTATION
K Freson, L de Waele, P Vandenberghe, R de Vos, P Vyas, C van Geet (University of Leuven, Leuven, Belgium)

ANNEXIN II IS OVER EXPRESSED IN HCG-PML-RAR
LEUKEMIC MICE AND IS ASSOCIATED WITH HIGHER LEVELS OF TISSUE PLASMINOGEN ACTIVATOR (TPA)
R Jacomo, B Santana-Lemos, AS Lima, P Assis, AP Lima, L Oliveira, A Garcia, MC Pintao, L Pontes, R Falcao, E Rego (Faculdade de Medicina de Ribeirão Preto, Ribeirao Preto, Brazil)

FREQUENCY, TYPES AND MANAGEMENT OF BLEEDING EPISODES IN ACQUIRED VON WILLEBRAND SYNDROME: A FIVE-YEAR PROSPECTIVE STUDY IN A COHORT OF 18 PATIENTS WITH CHRONIC LYMPHO-MYELOPROLIFERATIVE DISORDERS (LPD/MPD)
A Federici, F Rezzonico, P Bucciarelli, A Artoni, G Cozzi, MT Canciani (University of Milan, Milan, Italy)

IDIOPATHIC VEIN THROMBOSIS: IDENTIFICATION OF POPULATIONS AT DIFFERENT RISK OF RELAPSE FOLLOWING ORAL ANTICOAGULANT TREATMENT. THE RESULTS OF THE 'EXTENDED-DACUS STUDY'
S Siragusa, A Malato, G Saccullo, L Lo Coco, A Iorio, A Tuttolomondo, A Pinto, A Casuccio, V Abbadessa, G Mariani (University of Palermo, Palermo, Italy)

PROPOSAL OF A NEW, COMPREHENSIVE CYTOGENETIC SCORING SYSTEM FOR PRIMARY MDS
J Schanz, H Tüchler, F Sole, M Mallo, B Hildebrandt, M Slovak, K Ohyashiki, C Steidl, C Fonatsch, M Pfeilstöcker, T Nösslinger, P Valent, A Giagounidis, C Aul, M Lübbert, R Stauder, O Krieger, M LeBeau, J Bennett, P Greenberg, U Germing, D Haase (University of Goettingen, Goettingen, Germany)

DETECTION OF RARE ABNORMALITIES AND KARYOTYPE EVOLUTION IN MDS PATIENTS FROM PERIPHERAL BLOOD: FIRST RESULTS FROM THE MULTICENTER GERMAN PROSPECTIVE DIAGNOSTIC CD34+FISH-STUDY
F Braulke, J Schanz, S Detken, J Seraphin, M Metz, T Brümmendorf, K Goetze, U Platzbecker, L Truemper, D Haase (University Medicine, Goettingen, Germany)

DETECTION OF RARE ABNORMALITIES AND KARYOTYPE EVOLUTION IN MDS PATIENTS FROM PERIPHERAL BLOOD: FIRST RESULTS FROM THE MULTICENTER GERMAN PROSPECTIVE DIAGNOSTIC CD34+FISH-STUDY
F Braulke, J Schanz, S Detken, J Seraphin, M Metz, T Brümmendorf, K Goetze, U Platzbecker, L Truemper, D Haase (University Medicine, Goettingen, Germany)

AZACITIDINE TREATMENT PATTERNS, HEMATOLOGIC IMPROVEMENT,AND TOLERABILITY IN A LARGE GROUP OF ELDERLY PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) IN THE AVIDA REGISTRY TREATED IN A COMMUNITY SETTING
R Komrokji, A List, M Sekeres, M Narang, A Swern, K Sullivan, T Street, D Grinblatt (Moffitt Cancer Center, Tampa, USA)

GENETIC TYPING OF CBL, ASXL, AML, TET, AND JAK2 IN JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) REVEALS A GENETIC PROFILE DISTINCT FROM CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
B Pérez, O Kosmider, B Cassinat, A Renneville, J Lachenaud, S Kaltenbach, Y Bertrand, A Baruchel, C Chomienne, M Fontenay, C Preudhomme, H Cavé (AP-HP, Hôpital Robert Debré (INSERM U940 IUH Hôpital Saint-Louis, Paris, France)

HS1 HAS A CENTRAL ROLE IN LEUKEMIC B CELLS TRAFFICKING AND HOMING
C Scielzo, MT Bertilaccio, G Simonetti, E Ten Hacken, M Muzio, A Dagklis, C Fazi, M Ponzoni, V Caiolfa, U Restuccia, A Bachi, P . Ghia, F Caligaris- Cappio (Istituto Scientifico San Raffaele, Milano, Italy)

THE GENETICS OF RICHTER SYNDROME IDENTIFIES DISEASE HETEROGENEITY AND IS AN INDEPENDENT PREDICTOR OF SURVIVAL POST TRANSFORMATION
D Rossi, V Spina, C Deambrogi, L Laurenti, K Stamatopoulos, M Lucioni, L Arcaini, G Rocque, J Malik, J Chang, E Chigrinova, J Nomdedeu, F Forconi, R Marasca, C Besson, M Paulli, A Carbone, L Larocca, V Gattei, F Bertoni, K Young, G Gaidano (Division of Hematology, Amedeo Avogadro University, Novara, Italy)

SELECTIVE INHIBITORS OF THE SPLEEN TYROSINE KINASE (SYK) BLOCK CELL SURVIVAL AND MIGRATION IN CHRONIC LYMPHOCYTIC LEUKEMIA
J Hoellenriegel, G Coffey, U Sinha, A Pandey, W Wierda, M Keating, J Burger (MD Anderson Cancer Center, Houston, USA)

IMPACT OF TP53 MUTATIONS ON OUTCOME: RESULTS FROM THE CLL8 TRIAL (FC VS. R-FC) OF THE GCLLSG
T Zenz, P Hoth, R Busch, H Helfrich, D Winkler, A Bühler, N Patten, N Truong, L Wu, G Fingerle-Rowson, K Fischer, A Fink, U Jäger, S Böttcher, M Kneba, M Wenger, M Mendila, M Hallek, H Döhner, S Stilgenbauer (University of Ulm, Ulm, Germany)

HUMAN LEUKOCYTE ANTIGEN MATCHING AND CONDITIONING IMPACT ON LONG-TERM TRANSPLANT OUTCOME AFTER ALLOGENEIC HSCT FOR CHRONIC LYMPHOCYTIC LEUKEMIA: STUDY FROM THE EBMT REGISTRY
M Michallet, M Sobh, D Milligan, S Morisset, D Niederweiser, V Koza, T Ruutu, N Russell, L Verdonck, N Dhedin, A Vitek, M Boogaerts, L Vindelov, J Finke, V Dubois, A van Biezen, R Brand, P Dreger (Edouard Herriot Hospital, Lyon, France)

OUTCOME OF PATIENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA (APL) TREATED WITH THE COMBINATION OF ALL-TRANS RETINOIC ACID (ATRA), ARSENIC TRIOXIDE (ATO), WITH OR WITHOUT GEMTUZUMAB OZOGAMICIN (GO)
F Ravandi, J Cortes, S Faderl, S O'Brien, S Pierce, M Brandt, G Garcia- Manero, H Kantarjian (University of Texas - M. D. Anderson Cancer Center, Houston, USA)

LONG-TERM OUTCOME OF AML PATIENTS ACCORDING TO THE NEW GENETIC RISK CLASSIFICATION OF THE EUROPEAN LEUKEMIANET RECOMMENDATIONS: EVALUATION OF THE PROPOSED REPORTING SYSTEM IN A COHORT OF 1507 PATIENTS
C Röllig, C Thiede, W Aulitzky, M Bornhäuser, H Bodenstein, R Stuhlmann, M Kramer, B Mohr, F Stölzel, M von Bonin, H Wandt, G Ehninger, M Schaich (Universitätsklinikum Dresden, Dresden, Germany)

FACTORS DETERMINING CLINICAL RESPONSE TO 5'-AZACITDINE AND SODIUM VALPROATE COMBINATION THERAPY IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASIA
C Craddock, S Siddique, T McSkeane, M Griffiths, S Pillai, J Cavenagh, P Vyas (Queen Elizabeth Hospital, Birmingham, United Kingdom)

LOW DOSE GEMTUZUMAB OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN (GO-FLAI) AS INDUCTION THERAPY IN CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS YOUNGER THAN 65 YEARS. INTERIM RESULTS FROM A PHASE III MULTICENTER PROSPECTIVE CLINICAL TRIAL (MYFLAI07- NCT.00909168).
A Candoni, G Martinelli, F Gherlinzoni, C Papayanidis, I Iacobucci, M Gottardi, G Visani, E Simeone, S Paolini, B Lama, A Michelutti, A Isidori, P Piccaluga, G Sparaventi, M Malagola, D Russo, M Baccarani, R Fanin (Division of Hematology and BMT, Udine, Italy)

A PHASE II MULTICENTRE STUDY WITH ELACYTARABINE IN LATE STAGE ACUTE MYELOID LEUKAEMIA
S O’Brien, D Rizzieri, N Vey, F Ravandi, U Krug, M Sekeres, M Dennis, A Venditti, T Jacobsen, B Nilsson, F Giles (University of Texas MD Anderson Cancer Center, Houston, USA)

CLONAL GENETIC EVOLUTION IN HUMAN ACUTE LYMPHOBLASTIC LEUKEMIA TRANSPLANTED INTO IMMUNE-DEFICIENT MICE
E Clappier, B Gerby, S Quentin, F Touzri, A Baruchel, P Ballerini, F Pflumio, J Soulier (CEA, Fontenay-aux-Roses, France)

NEXT GENERATION TRANSCRIPTOME RESEQUENCING IDENTIFIES NOVEL POINT MUTATIONS, GENE EXPRESSION AND ALTERNATIVE SPLICING PROFILES IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
I Iacobucci, A Ferrarini, M Sazzini, A Lonetti, E Giacomelli, L Xumerle, A Ferrari, C Papayannidis, S Paolini, D Cilloni, MC Abbenante, V Guadaguolo, A Vitale, F Pane, S Soverini, M Baccarani, M Delledonne, G Martinelli (Institute of Hematology „Seràgnoli„, Bologna, Italy)

MIRNA-155 TARGETS BCL6 AND HDAC4 IN A MURINE B-CELL LEUKEMIA MODEL: A PARADIGM SHIFT IN THE ONCOGENIC MECHANISMS OF MICRORNAS
S Shukhinder, S Costinean, R Neinast, M Parthum, C Croce, R Garzon (The Ohio State university, Columbus, USA)

LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION
I Iacobucci, A Ferrari, A Lonetti, C Papayannidis, V Guadaguolo, C Storlazzi, E Ottaviani, MC Abbenante, S Paolini, S Parisi, D Cilloni, S Soverini, F Pane, A Vitale, B Lama, R Foà, M Baccarani, G Martinelli (Institute of Hematology „Seràgnoli„, Bologna, Italy)

PARALOG 4 GENES HOXA4 AND HOXB4 INDUCE A STRONG EXPANSION OF B-CELL PROGENITORS IN VITRO IN THE CONTEXT OF E2A-PBX
M Fournier, M Hassawi, H Frison, CE Lebert-Ghali, E Shestakova, J Bijl (Centre de Recherche Hopital Maisonneuve-Rosemont, Montreal, Canada)

MICRORNA-DEPENDENT MODULATION OF HISTONE ACETYLATION IN WALDENSTROM'S MACROGLOBULINEMIA
A Roccaro, A Sacco, A Azab, F Azab, T Ngo, P Maiso, G Rossi, M Ghobrial (Spedali Civili di Brescia, Brescia, Italy)

PRIMARY WALDESNTROM MACROGLOBULINEMIA (WM) CELLS HARBOR CONSTITUTIVE ACTIVATION OF PI3K/AKT AND MTOR PATHWAYS
A Roccaro (Spedali Civili di Brescia, Brescia, Italy)

RITUXIMAB MAINTENANCE FOR 2-YEARS SIGNIFICANTLY IMPROVES THE OUTCOME OF PATIENTS WITH UNTREATED HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA AFTER RESPONSE TO IMMUNOCHEMOTHERAPY: RESULTS OF THE PRIMA STUDY
G Salles, J Catalano, P Feugier, F Offner, R Bouabdallah, D Caballero, P Brice, L Moller Pedersen, C Haioun, D Belada, A Delmer, D Simpson, H Tilly, S Leppa, P Soubeyran, A Hagenbeek, O Casasnovas, I Tanin, C Ferme, M Gomes Da Silva, C Sebban, R Pettengell, J Estell, G Milone, A Sonnet, A López-Guillermo, J Seymour, L Xerri (Hospices Civils de Lyon & Université Claude Bernard, Pierre-Bénite, France)

PROMISING EFFICACY WITH THE NEW ANTI-CD20 ANTIBODY GA101 IN HEAVILY PRE-TREATED PATIENTS - FIRST RESULTS FROM A PHASE II STUDY IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NHL (INHL)
A Salles, F Morschhauser, C Thieblemont, P Solal-Celigny, T Lamy, H Tilly, P Feugier, S Le Gouill, E Gyan, R Bouabdallah, M Wenger, J Birkett, G Cartron (Hospices Civils de Lyon, Lyon, France)

CD3/CD19 BISPECIFIC BITE® ANTIBODY BLINATUMOMAB TREATMENT OF NON-HODGKIN LYMPHOMA (NHL) PATIENTS: 60 μG/M2/D BY CONTINUOUS INFUSION IS TOLERABLE AND RESULTS IN DURABLE RESPONSES
M Goebeler, A Viardot, R Noppeney, S Knop, M Topp, D Nagorsen, G Zugmaier, M Klinger, M Schmidt, P Klappers, P Kufer, H Einsele, R Bargou (University Hospital Wuerzburg, Wuerzburg, Germany)

A PHASE 3 STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE COMBINED WITH MELPHALAN AND PREDNISONE IN PATIENTS = 65 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
A Palumbo, M Dimopoulos, M Delforge, R Hajek, M Kropff, MT Petrucci, Z Yu, L Herbein, J Mei, C Jacques, J Catalano (University of Torino, Torino, Italy)

MP VERSUS MPT FOR PREVIOUSLY UNTREATED ELDERLY PATIENTS WITH MULTIPLE MYELOMA: A META ANALYSIS OF SURVIVAL OF 1682 INDIVIDUAL PATIENT DATA FROM 6 RANDOMIZED CLINICAL TRIALS
A Waage, A Palumbo, C Hulin, M Beksac, P Fayers, JY Mary, S Bringhen, P Sonneveld, P Wijermans, T Facon (Department of Hematology, Trondheim, Norway)

A PROSPECTIVE RANDOMIZED TRIAL OF BORTEZOMIBMELPHALAN- PREDNISONE-THALIDOMIDE FOLLOWED BY CONTINUOUS BORTEZOMIB-THALIDOMIDE FOR INITIAL THERAPY OF MULTIPLE MYELOMA: EFFECT OF AGE AND CO-MORBIDITIES
A Palumbo, S Bringhen, D Rossi, M Cavalli, R Ria, M Offidani, C Nozzoli, L Baldini, L De Rosa, G De Sabbata, AM Liberati, C Crippa, F Ciambelli, V Callea, M Spriano, F Ferrara, F Elice, M Galli, J Peccatori, L Catalano, M Rizzo, R Marasca, F Pisani, M Cavo, M Petrucci, P Musto, P Omedè, A Larocca, G Gaidano, M Boccadoro (A.O.U. San Giovanni Battista, Torino, Italy)

IMMUNOPHENOTYPIC RESPONSES CAN BE ACHIEVED IN ELDERLY MULTIPLE MYELOMA PATIENS TREATED WITH NOVEL AGENTS
B Paiva, M Vidriales, J Martinez, A Oriol, E Redondo, M Montalban, M Mateos, N Gutierrez, L Lopez-Corral, J Perez, A Martin, M Terol, Y Gonzalez, Echebeste, J Hernandez, F De Arriba, R De Paz, J Blade, J Lahuerta, J San Miguel (Hospital Universitario Salamanca, Salamanca, Spain)

ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN 895 ELDERLY MYELOMA PATIENTS TREATED WITH MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF 3 MULTICENTER ITALIAN TRIALS
F Gay, A Larocca, MT Petrucci, P Musto, AM Liberati, V Callea, R Ria, T Caravita, C Cangialosi, M Grasso, M Offidani, P Pregno, F Patriarca, M Galli, M Cavo, L Catalano, C Nozzoli, T Guglielmelli, R Zambello, F Pisani, V Montefusco, F Rossini, V De Stefano, B Lupo, F Di Raimondo, G Gaidano, M Boccadoro, A Palumbo (A.O.U. San Giovanni Battista, Torino, Italy)

A GENETIC VARIANT OF MLH, A GENE INVOLVED IN DNA MISMATCH REPAIR, IS AN INDEPENDENT PREDICTOR OF OVERALL SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP
D Rossi, S Rasi, A Fabbri, F Forconi, A Bruscaggin, A Di Rocco, M Fangazio, S Franceschetti, L De Paoli, R Bruna, A Chiappella, E Pogliani, F Lauria, U Vitolo, S Hohaus, M Martelli, R Foà, G Gaidano (Division of Hematology, Amedeo Avogadro University, Novara, Italy)

ROMIDEPSIN EXPERIENCE IN 317 PATIENTS WITH T-CELL LYMPHOMAS
B Coiffier, S Horwitz, S Whittaker, B Pro, T Robak, A Samtsov, Y Kim, M Prince, F Foss, R Piekarz, J Nichols, S Bates (Hospices Civils de Lyon, Pierre Benite, France)

ANTI-CD22 IMMUNOCONJUGATE INOTUZUMAB OZOGAMICIN (CMC-544) + RITUXIMAB: CLINICAL ACTIVITY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR ‘AGGRESSIVE' LYMPHOMA
G Verhoef, N Dang, M Smith, F Offner, P Johnson, A Rohatiner, J Kaufman, E Gine, B Coiffier, M Czuczman, J Foran, S Durrant, S Hua, E Vandendries, J Boni, L Fayad (UZ Leuven, Leuven, Belgium)

LENALIDOMIDE MONOTHERAPY IS CLINICALLY ACTIVE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A POOLED ANALYSIS OF DATA FROM 2 PHASE II STUDIES (NHL-002/003)
M Czuczman, J Vose, PL Zinzani, C Reeder, R Buckstein, C Haioun, R Bouabdallah, J Polikoff, A Ervin-Haynes, T Witzig (Roswell Park Cancer Institute, Buffalo, USA)

SUSTAINED SURVIVAL ADVANTAGE AFTER A MEDIAN FOLLOW-UP OF 5 YEARS FOR IMMUNO-CHEMOTHERAPY (R-MCP) VERSUS CHEMOTHERAPY ALONE (MCP) IN ADVANCED FOLLICULAR LYMPHOMA - UPDATE OF THE OSHO#39 TRIAL
M Herold, G Maschmeyer, V Lakner, G Dölken, G Ehninger, M Hänel, R Rohrberg, A Hochhaus, A Neubauer, L Fischer, U von Grünhagen, S Hahnfeld, F Hoffmann, M Wußling, W Stein, E Kettner, D Hähling (Helios Klinikum Erfurt, Erfrurt, Germany)

CELL OF ORIGIN INFLUENCES LEUKEMIA STEM CELL PHENOTYPE
V Krivtsov, C Stubbs, U Sinha, J Wang, L Bullinger, L Kung, A Armstrong (Children's Hospital, Boston, USA)

DEVELOPMENT OF A MOUSE MODEL OF ONCOGENIC COOPERATION IN DS-AML AND IDENTIFICATION OF HUMAN CHROMOSOME 21 GENES THAT FACILITATE LEUKEMOGENESIS
S Malinge (Northwestern University, Chicago, USA)

A CONDITIONAL KNOCK-IN ALLELE OF THE TYPE A CYTOPLASMIC NUCLEOPHOSMIN MUTATION COOPERATES WITH A NOVEL SLEEPING BEAUTY TRANSPOSON TO CAUSE ACUTE MYELOID LEUKAEMIA IN MICE
G Vassiliou, J Cooper, R Rad, S Rice, M Arends, P Wright, L Rad, R Banerjee, K Yusa, P Ellis, C Grove, A Uren, B Huntly, D Adams, J Li, A Bradley (Wellcome Trust Sanger Institute, Cambridge, United Kingdom)

MEIS1 CONTROLS SUSCEPTIBILITY TO MN1-INDUCED LEUKEMIC TRANSFORMATION
M Heuser, H Yun, B Argiropoulos, E Yung, F Kuchenbauer, G Park, C Lai, M Leung, G Lin, I Hamwi, N Thiessen, G Robertson, M Hirst, M Marra, A Ganser, R Humphries (Hannover Medical School, Hannover, Germany)

EXPRESSION OF THE CYTOPLASMIC NPM1 MUTANT (NPMC+) CAUSES THE EXPANSION OF HEMATOPOIETIC CELLS IN ZEBRAFISH
N Bolli, E Payne, A Johnston, C Grabher, B Falini, J Kanki, T Look (Dana-Farber Cancer Institute, Boston, USA)

ISOLATION AND KILLING OF CANDIDATE CML STEM CELLS BY ANTIBODY TARGETING OF IL1RAP
M Järås, P Johnels, N Hansen, H Ågerstam, M Rissler, C Lassen, T Olofsson, O Bjerrum, J Richter, T Fioretos (Lund University, Lund, Sweden)

WHOLE-TRANSCRIPTOME SEQUENCING IN CHRONIC MYELOID LEUKEMIA AT DIAGNOSIS AND AT THE TIME OF PROGRESSION TO BLAST CRISIS REVEALS NOVEL GENE MUTATIONS
S Soverini, A Poerio, A Ferrarini, I Iacobucci, M Sazzini, E Giacomelli, L Xumerle, S Colarossi, A Gnani, F Castagnetti, F Palandri, G Gugliotta, M Amabile, G Rosti, M Baccarani, M Delledonne, G Martinelli (University of Bologna, Bologna, Italy)

HIGH-RESOLUTION GENOME-WIDE ANALYSIS OF COPY NUMBER ALTERATIONS/LOSS OF HETEROZIGOSITY IN CHRONIC MYELOID LEUKEMIA SHOWS THAT HIGH SOKAL RISK PATIENTS HAVE MULTIPLE LOSSES TARGETING DNA REPAIR GENES
S Soverini, S Colarossi, A Gnani, A Astolfi, S Formica, F Castagnetti, F Palandri, G Gugliotta, G Rosti, A Poerio, I Iacobucci, M Amabile, G Marzocchi, S Luatti, S Durante, C Terragna, N Testoni, M Baccarani, G Martinelli (University of Bologna, Bologna, Italy)

DISSECTING MOLECULAR BASES OF HIGH SOKAL VERSUS LOW SOKAL RISK IN CHRONIC MYELOID LEUKEMIA PATIENTS BY GENE EXPRESSION PROFILES OF CD34+ CELLS AT DIAGNOSIS
C Terragna, S Durante, A Astolfi, F Palandri, F Castagnetti, N Testoni, I Iacobucci, S Soverini, M Amabile, A Poerio, G Alimena, M Breccia, F Pane, G Saglio, G Rosti, M Baccarani, G Martinelli (Institute of Hematology „Seràgnoli„, Bologna, Italy)

SEVERE TELOMERIC LOSS OCCURS IN PH-NEGATIVE HEMATOPOIESIS EMERGING AFTER SUCCESSFUL TREATMENT OF CHRONIC MYELOID LEUKEMIA AND ASSOCIATES WITH ACQUIRED CYTOGENETIC LESIONS AND LOW HEMOGLOBIN LEVELS
C Lobetti Bodoni, E Genuardi, R Passera, D Sia, E Crisà, G Grignani, V Giai, A Rocci, L Monitillo, D Drandi, M Zanni, M Boi, G Isaia, E Bernocco, M Lunghi, E Abruzzese, F Radaelli, M Pini, P Pregno, G Gaidano, M Boccadoro, C Carlo-Stella, D Ferrero, M Ladetto (University of Torino, A.O.U. San Giovanni Battista, Turin, Italy)

UBIQUITINATION OF THE ERYTHROPOIETIN RECEPTOR IS
NOT REQUIRED FOR EPO-INDUCED INTERNALIZATION BUT IS
IMPORTANT FOR ENDO-LYSOSOMAL SORTING AND DOWNREGULATION
J Huang, R Sulahian, G Bulut (University of Texas Southwestern Medical
Center, Dallas, USA)

A NOVEL APPROACH TO CELL-TARGETED COMPLEMENT INHIBITION IN PNH: THE HUMAN COMPLEMENT RECEPTOR 2/ FACTOR H FUSION PROTEIN TT30 PREVENTS BOTH HEMOLYSIS AND UPSTREAM C3-OPSONIZATION OF PNH ERYTHROCYTES
C Pascariello, C Selleri, L Del Vecchio, M Sica, C Horvath, M Holers, L Luzzatto, A Risitano (Department of Biochemistry and Medical Biotechnologies, Federico II University, Naples, Italy)

THE BRAZILIAN HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN TYPE MUTATION REDUCES THE BINDING OF THE NF-E1/YY1 TRANSCRIPTION FACTOR AND MAY BE RESPONSIBLE FOR THE REACTIVATION OF THE GAMMA GLOBIN GENE
F Roversi, A Cunha, C Lanaro, AF Brugnerotto, DS Souza, D Albuquerque, F Costa (UNICAMP, Campinas, Brazil)

OUTCOMES OF UNRELATED CORD BLOOD TRANSPLANT IN PATIENTS WITH HEMOGLOBINOPATHIES
A Ruggeri, M Eapen, A Scaradavou, D Purtill, M Cairo, M Bhatia, J Kurtzberg, J Wagner, A Fasth, L Lo Nigro, W Chaves, M Walters, E Gluckman, V Rocha (Eurocord-Hopital Saint Louis, Paris, France)

THE ROLE OF VLA-4 AND CX3CR1 ON RECRUITMENT OF T CELLS INTO BONE MARROW IN PATIENTS WITH APLASTIC ANEMIA
J Peng, R Ren, M Ma, Y Yu, X Xu, H Hou (Qilu Hospital, Jinan, China)

THE ROLE OF MEIS1 IN PRIMITIVE AND DEFINITIVE HAEMATOPOIESIS AND VASCULAR PATTERNING DURING ZEBRAFISH DEVELOPMENT
A Cvejic, J Serbanovic-Canic, D Stemple, W Ouwehand (University of Cambridge, Cambridge, United Kingdom)

C/EBPA INSTRUCTS EARLY THYMIC PROGENITORS TOWARDS CELLS WITH MYELOID AND DENDRITIC CELL POTENTIAL
A Wölfler, J Haanstra, M Valkhof, E Vroegindeweij, P van Strien, A Danenvan Oorschot, T Cupedo, I Touw (Medical University Graz, Graz, Austria)

CEBPA DOUBLE MUTATIONS IMPACT FAVORABLY ON THE OUTCOME OF OLDER ADULTS WITH WILD-TYPE NPM1 CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA AND ARE ASSOCIATED WITH DISTINCT GENE AND MICRORNA EXPRESSION
H Becker, G Marcucci, K Maharry, M Radmacher, Y Wu, K Mrozek, S Whitman, D Margeson, K Holland, S Schwind, K Metzeler, B Powell, T Carter, J Kolitz, M Wetzler, A Carroll, M Baer, J Moore, M Caligiuri, R Larson, C Bloomfield, Cancer and Leukemia Group B (The Ohio State University, Columbus, USA)

MICRORNA NETWORKS IN LEUKEMIA
R Garzon, G Gamberroni, R Visone, Y Pekarsky, M Galasso, G Calin, M Andreeff, C Croce (The Ohio State university, Columbus, USA)

ABERRATIONS OF MULTIPLE GENES REGULATING NF KAPPA B PATHWAY IN MALIGNANT LYMPHOMA
M Kato, K Yoshida, M Sanada, I Kato, Y Sato, J Takita, K Takeuchi, R Kawahata, A Niwa, K Nakazaki, J Nomoto, T Igarashi, M Kurokawa, S Chiba, S Mori, Y Ishikawa, K Okamoto, K Tobinai, H Nakagama, T Nakahata, T Yoshino, Y Kobayashi, S Ogawa (The University of Teikyo, Tokyo, Japan)

A PEDIATRIC-INSPIRED INTENSIFIED THERAPY OF ADULTS T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA REVEALS THE FAVORABLE OUTCOME OF NOTCH1/FBXW7 MUTATIONS, BUT NOT OF LOW ERG/BAALC EXPRESSION: A GRAALL STUDY
R Ben Abdelali, V Asnafi, A Buzyn, E Lengliné, S Le noir, N Ifrah, E Macintyre, H Dombret (Necker Hospital, Paris, France)

IKZF1 DELETIONS PREDICT RELAPSE IN UNIFORMLY TREATED PEDIATRIC PRECURSOR B-ALL
R Kuiper, E Waanders, V VanderVelden, C VanderSchoot, S VanReijmersdal, R Venkatachalam, B Scheijen, E Sonneveld, J VanDongen, A Veerman,F van Leeuwen, A GeurtsvanKessel, P Hoogerbrugge (Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands)

PROLONGED LEUKEMIA FREE SURVIVAL FOLLOWING BLINATUMOMAB (ANTI-CD19 BITE®) TREATMENT OF PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD) OF B PRECURSOR ALL: UPDATED RESULTS OF A PHASE II STUDY
C Bargou, G Zugmaier, N Goekbuget, S Neumann, H Horst, T Raff, M Brueggemann, A Viardot, M Schmid, M Schaich, M Stelljes, M Goebeler, H Pfeifer, O Ottmann, T Burmeister, E Degenhard, M Schmidt, H Einsele, P Kufer, M Klinger, D Nagorsen, D Hoelzer, S Topp (Department of Internal Medicine II, Division of Hematology and Medical Oncology,, Würzburg, Germany)

IMPACT OF ALLOGENEIC STEM CELL TRANSPLANTATION ON TYROSINE KINASE DOMAIN MUTATIONS AND MINIMAL RESIDUAL DISEASE LEVELS IN PATIENTS WITH PHILADELPHIA-CHROMOSOME- POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
H Pfeifer, S Wystub, A Schmidt-Tanguy, M Stadler, J Dengler, W Bethge, T Lange, J Meyer, U Platzbecker, B Wassmann, P Brueck, N Goekbuget, H Serve, D Hoelzer, O Ottmann (Goethe University Frankfurt, Frankfurt am Main, Germany)

THE NOVEL CALICHEAMICIN-CONJUGATED CD22 ANTIBODY INOTUZUMAB OZOGAMICIN (CMC-544) EFFECTIVELY KILLS PRIMARY PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA CELLS
J de Vries, C Zwaan, M de Bie, J Voerman, M den Boer, J van Dongen, P Kelly, V van der Velden (Erasmus MC, Rotterdam, The Netherlands)

THE ROLE OF THE IAP LIVIN IN MEGAKARYOCYTES DIFFERENTIATION AND THROMBOPOIESIS
I Abd-Elrahman, I Deutsch, S Kay, N Noyman, R Perlman, D Ben-Yehuda (Hadassah-Hebrew University Medical Center, Jerusalem, Israel)

AN ENU-DERIVED MOUSE MODEL OF MYH9-RELATED DISEASE IDENTIFIED BY MASSIVELY MULTIPLE PARALLEL SEQUENCING
E Berndl, N Anderson, Z Milenkovic, J McPherson, D Barber, W Stanford (Univeristy of Toronto, Toronto, Canada)

EFFICACY OF RITUXIMAB IN COMBINATION WITH DEXAMETHASONE VS DEXAMETHASONE IN NEWLY DIAGNOSED PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA - AN INTERIM ANALYSIS OF A PROSPECTIVE RANDOMISED STUDY
S Gudbrandsdottir, H Frederiksen, I Helleberg, B Jensen, L Kjeldsen, T Klausen, H Larsen, HT Mourits-Andersen, CH Nielsen, OJ Nielsen, T Plesner, S Pulczynski, D Roennow-Jessen, HC Hasselbalch, H Birgens (Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark)

RESULTS OF BONE MARROW EXAMINATIONS IN PATIENTS WITH CHRONIC IDIOPATHIC (IMMUNE) THROMBOCYTOPENIC PURPURA TREATED WITH ELTROMBOPAG FOR MORE THAN ONE YEAR
J Bussel, M Saleh, O Meyer, H Frederiksen, D Johnni, M Aivado, A Brainsky (Weill Medical College of Cornell University, New York, USA)

THE EFFECT OF DESMOPRESSIN (DDAVP) ON PLATELET FUNCTION: SELECTIVE AND MARKED ENHANCEMENT OF PLATELET PROCOAGULANT ACTIVITY
L Alberio, T Conte, M Pavicic, M Reusser, M Stutz, C Thürlemann, P Keller, G Colucci (Inselspital University Hospital, Bern, Switzerland)